Roche Feels Lucentis Market Could Move On Before Biosimilars Debut
Two New Ophthalmology Products Will Challenge Biosimilars, Roche Believes
Executive Summary
Roche upended expectations for biosimilar Lucentis (ranibizumab) in the US, with a recent licensing deal signed with biosimilar sponsor Samsung Bioepis keeping the first proposed rival from the market until June 2022. The originator is also confident its pipeline assets will stem competition.
You may also be interested in...
Xbrane’s Ranibizumab Marches On With US FDA Filing Imminent
With Samsung Bioepis already holding US and EU approvals for biosimilar ranibizumab, Swedish sponsor Xbrane Biopharma says 12-month Phase III data supports ongoing registration of the Lucentis rival in both regions.
How Samsung Bioepis Is Laying A Path For Ophthalmic Biosimilars
With the first approved rival to Lucentis in both the EU and US, Samsung Bioepis is laying the groundwork for biosimilars to break into ophthalmology ahead of launching its Byooviz version of ranibizumab, explains vice-president of commercial strategy Josh Lee.
Still ‘Work To Be Done’ After Ranibizumab Approval, Says Samsung Bioepis
Samsung Bioepis recently broke new ground with the first US approval for a biosimilar with ophthalmic indications. But, senior vice-president and development division leader Kyung-Ah Kim tells Generics Bulletin, there remains work to be done to ensure that ophthalmic biosimilars can meet their full potential.